These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18213449)

  • 1. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
    Perrotti D; Neviani P
    Cancer Metastasis Rev; 2008 Jun; 27(2):159-68. PubMed ID: 18213449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
    Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
    Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein phosphatase 2A: a target for anticancer therapy.
    Perrotti D; Neviani P
    Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A.
    Yang X; Yan T; Gong Y; Liu X; Sun H; Xu W; Wang C; Naren D; Zheng Y
    Oncotarget; 2017 Apr; 8(15):24437-24448. PubMed ID: 28445932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
    Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
    Sangodkar J; Perl A; Tohme R; Kiselar J; Kastrinsky DB; Zaware N; Izadmehr S; Mazhar S; Wiredja DD; O'Connor CM; Hoon D; Dhawan NS; Schlatzer D; Yao S; Leonard D; Borczuk AC; Gokulrangan G; Wang L; Svenson E; Farrington CC; Yuan E; Avelar RA; Stachnik A; Smith B; Gidwani V; Giannini HM; McQuaid D; McClinch K; Wang Z; Levine AC; Sears RC; Chen EY; Duan Q; Datt M; Haider S; Ma'ayan A; DiFeo A; Sharma N; Galsky MD; Brautigan DL; Ioannou YA; Xu W; Chance MR; Ohlmeyer M; Narla G
    J Clin Invest; 2017 Jun; 127(6):2081-2090. PubMed ID: 28504649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia.
    Ramaswamy K; Spitzer B; Kentsis A
    Front Oncol; 2015; 5():16. PubMed ID: 25699237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
    Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
    Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
    Arriazu E; Pippa R; Odero MD
    Front Oncol; 2016; 6():78. PubMed ID: 27092295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
    Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
    J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
    Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
    Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL
    Lai D; Chen M; Su J; Liu X; Rothe K; Hu K; Forrest DL; Eaves CJ; Morin GB; Jiang X
    Sci Transl Med; 2018 Feb; 10(427):. PubMed ID: 29437150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
    Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
    J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway.
    McConnell JL; Gomez RJ; McCorvey LR; Law BK; Wadzinski BE
    Oncogene; 2007 Sep; 26(41):6021-30. PubMed ID: 17384681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure, regulation, and pharmacological modulation of PP2A phosphatases.
    Lambrecht C; Haesen D; Sents W; Ivanova E; Janssens V
    Methods Mol Biol; 2013; 1053():283-305. PubMed ID: 23860660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.
    Ciccone M; Calin GA; Perrotti D
    Front Oncol; 2015; 5():21. PubMed ID: 25763353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
    Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
    Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
    Sangodkar J; Farrington CC; McClinch K; Galsky MD; Kastrinsky DB; Narla G
    FEBS J; 2016 Mar; 283(6):1004-24. PubMed ID: 26507691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein phosphatase 2A regulatory subunits and cancer.
    Eichhorn PJ; Creyghton MP; Bernards R
    Biochim Biophys Acta; 2009 Jan; 1795(1):1-15. PubMed ID: 18588945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.